WO2001056466A9 - Method for evaluating novel stroke treatments using a tissue risk map - Google Patents
Method for evaluating novel stroke treatments using a tissue risk mapInfo
- Publication number
- WO2001056466A9 WO2001056466A9 PCT/US2001/003502 US0103502W WO0156466A9 WO 2001056466 A9 WO2001056466 A9 WO 2001056466A9 US 0103502 W US0103502 W US 0103502W WO 0156466 A9 WO0156466 A9 WO 0156466A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- risk
- tissue
- further including
- infarction
- algorithms
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30016—Brain
Definitions
- Welch's approach provide a more sensitive approach for identifying salvageable tissue by demonstrating that a combination of T2 and ADC information provided better prediction of cellular necrosis than algorithms that used them separately and that a voxel-by- voxel analysis may better demonstrate the underlying heterogeneity in the lesion.
- These studies implemented their predictive algorithms using thresholding techniques in which tissue is classified as abnormal if a measured value, e.g., the apparent diffusion coefficient (ADC) or T2WI value, is 1.5-2 standard deviations away from its mean value in the contralateral hemisphere. Readily assessing the signatures' significance can therefore be complicated as the number of input parameters is increased (d inputs result in 2d states).
- a more appropriate model may be one in which the inputs are considered random variables and the output a probability variable. It would, therefore, be desirable to provide a voxel-by- voxel risk map indicating the probabilities that tissue will infarct. It would further be desirable to utilize the risk map to evaluate novel interventions.
- FIG. 8 is a flow diagram of an exemplary sequence of steps for evaluating stroke treatment in accordance with the present invention
- FIG. 9 is a further flow diagram for evaluating novel stroke treatment in accordance with the present invention.
- the risk map can be generated from acquired acute imaging data using a variety of techniques including linear generalized models (GLMs), general additive models (GAMs) and neural networks.
- LLMs linear generalized models
- GAMs general additive models
- a generalized linear model is used to combine DWI and PWI data.
- the GLM can be used to define a probability of tissue infarction y as set forth in Equation 1 below:
- EXAMPLE 1 Diffusion-weighted (DWI) and perfusion-weighted MR images (PWI) from acute stroke patients scanned within twelve hours of symptom onset were retrospectively studied and used to develop thresholding and generalized linear model (GLM) algorithms predicting tissue outcome as determined by follow-up MRI. The performances of the algorithms were evaluated for each patient by using receiver operating characteristic (ROC) curves. Imaging was performed on a 1.5T General Electric Signa MR instrument, with version
- the isotropic diffusion weighted image (DWI) was formed from the geometric mean of the high b- value single-shot images.
- the ADC image was calculated from the slope of the linear regression fit of the log of the high and low b-value images versus their b- values.
- the volumetric diffusion, perfusion and follow-up data were spatially coregistered utilizing an automated image registration software package, AIR 3.08 (UCLA, CA).
- the initial low b-value T2-weighted EPI, ADC, DWI and follow-up T2-weighted FSE images were coregistered to the same dimensions (128x128x11 or 128x128x10 voxels), orientation, and coordinates as the perfusion images using an affi ⁇ e, twelve-parameter transformation model and trilinear interpolation.
- Voxels from "normal" appearing gray matter in the unaffected, contralateral hemisphere from the coregistered initial T 2 images were outlined prior to generation of the predictive maps.
- tissue was classified as abnormal if the initial diffusion or perfusion values were greater than a specified number of standard deviations from the mean value measured in the contralateral non-infarcted gray matter regions.
- Tissue signature maps were generated using images calculated from the diffusion study (T 2 +ADC+DWI), images calculated from the perfusion study (CBF+CBN+MTT), and combinations of images from both studies.
- signature maps were generated using combinations of T2 and ADC with one perfusion parameter (CBF, CBV or MTT) and all six parameters (T2 + ADC + DWI + CBF + CBV + MTT).
- a threshold of 2 standard deviations from the mean of the contralateral values was used.
- tissue outcome was modeled as a binary variable (infarcted/non-infarcted), P, where the value 1 represented infarcted tissue and value 0 non-infarcted tissue.
- P infarcted/non-infarcted
- the probability of tissue infarcting can be represented by the logistic function recited below in Equation 2:
- the ⁇ term provides the base value for P if all of the input parameters, x, are zero.
- the ⁇ coefficients can be interpreted as the multiplicative effects on P due to changes in the input parameters.
- a supervised approach was utilized.
- training regions were selected by outlining brain tissue volumes that were clearly infarcted or non-infarcted in the ipsilateral hemisphere in the coregistered follow-up axial T 2 FSE images by a neuroradiologist blinded to the predictive map results. Care was taken to avoid including regions demonstrating chronic changes on T 2 , such as old stroke lesions or periventricular white matter abnormalities. Selection of normal voxels was also limited to the ipsilateral hemisphere in slices that showed evidence of infarction.
- the computed coefficients for each of the training datasets were compared to determine if they were significantly different (P>0.05) from the coefficients obtained using a dataset containing data from all patients.
- the average of the coefficients of the GLM algorithms obtained from the 14 training data subsets was also compared with the coefficients of the aggregate GLM algorithm. Two-tailed Z-tests were used for the statistical comparisons.
- the same infarcted and non-infarcted regions used in the training of the GLM algorithms were used.
- the performance of each of the algorithms was evaluated on its ability to accurately discriminate the infarcted from non-infarcted regions in the ipsilateral hemisphere.
- the number of voxels predicted to infarct that actually did infarct (true positives or TP)
- the number that did not infarct (false positives or FP) were tabulated.
- the number of voxels predicted not to infarct that remained non-infarcted were tracked, as well as those that became infarcted (false negatives or FN).
- GLM algorithms using different combinations of the possible six input parameters were evaluated and compared using data from all fourteen patients.
- rCBF resulted in the greatest reduction in the AIC, followed by rT 2 , then rADC and finally rCBV.
- rDWI and rMTT resulted in a further reduction of AIC and were therefore included in the combined diffusion and perfusion GLMs. Therefore, the optimal GLM algorithm by the AIC requires all six parameters. However, for the purpose of comparison, the GLM coefficients for all possible 63 GLMs were calculated.
- the OOPs are comparable for both thresholding and GLM algorithms.
- the "combined algorithms” have the greatest sensitivities at each of the specificities listed in Table 2.
- Both thresholding and GLM methods produce similar ROC curves when pooling results across the fourteen subjects.
- ROC curves were also generated on an individual patient basis and the area under the curves (AUC) calculated.
- AUC area under the curves
- the differences between the multivariate algorithms' AUCs were calculated for the thresholding and GLM algorithms.
- Diffusion and perfusion MR imaging were performed using published MGH imaging protocol and techniques.
- rCBV relative cerebral blood volume
- rCBF relative cerebral blood flow
- MTT mean transit time
- MR images were also obtained, which included axial T2 fast spin echo (FSE) and fluid attenuated inversion recovery (FLAIR) images, as well as 2D phase contrast MR angiography and sagittal TI weighted images.
- FSE fast spin echo
- FLAIR fluid attenuated inversion recovery
- 2D phase contrast MR angiography and sagittal TI weighted images were also underwent CT scanning prior to entering the study.
- a generalized linear model (GLM) of risk of tissue infarction was generated from retrospective studies of hyperacute cerebral ischemia patients who received diffusion and perfusion weighted imaging within twelve hours of presenting with symptoms. Only patients with cortical infarcts caused by occlusion of major cerebral arteries were included in the training data. Patients were excluded if they received novel therapeutic treatments or if there did not exist at least a five day follow-up study to confirm the extent of the infarct. This resulted in a total of fourteen patients for the training data set.
- the volumetric diffusion and perfusion data were coregistered utilizing an automated image registration software package (AIR 3.08). Utilizing a supervised learning algorithm and logistic regression, the parameters for the GLM were computed using coregistered data sets, as described in the previous section.
- x represents an input vector that can include an initial T2, ADC, rCBF (relative cerebral blood flow), rCBV (relative cerebral blood volume) and MTT (mean transmit time) data and ⁇ the calculated coefficients.
- Table 4 2x2 Contingency table based on improved outcome
- FIG. 6 shows an exemplary sequence of steps for evaluating a novel therapy in accordance with the present invention.
- prospective DWI and PWI data which is also referred to as acute MRI data
- acute MRI data is acquired from acute stroke patients prior or immediately post-treatment. Included in such data is placebo-treated or control patients acquired as part of a clinical trial, for example.
- follow-up conventional studies are acquired as a gold standard to determine the tissue's true outcome, F(I), e.g., infarcted or not-infarcted for each individual voxel, I.
- Conventional studies may include CT or MR, which can be coregistered with the acute MR studies.
- step 1070 the voxel predictions, f(I) are compared with actual results, F(I).
- one technique for comparing the results includes estimating the accuracy of the prediction by calculating the number of true positives (TP), false positives(FP), true negatives (TN)and false negatives (FN).
- step 2000 it is determined whether the tissue F(I) is infarcted based upon follow up imaging. If so, in step 2002 the prediction is compared to the actual tissue condition. If the tissue state matches the predicted tissue state, the voxel is classified at true positive TP in step 2004. If the prediction does not match, then in step 2006 the voxel is classified as false negative FN. If the tissue is not infarcted, as determined in step 2000, the prediction is compared to the actual tissue state in step 2008. The voxel is then classified as true negative TN in step 2010 if the prediction matches or as false positive FP in step 2012.
- FIG. 8 shows another embodiment of evaluating novel treatments with a risk map in accordance with the present invention.
- a risk map is generated using a GLM algorithm to evaluate the efficacy of a novel treatment.
- step 3000 patient DWI and PWI data is acquired at predetermined intervals.
- step 3002 the DWI and PWI data is combined, such as by using a GLM or GAM, to generate risk maps from the acquired data.
- the temporal evolution of treated and untreated patients is analyzed in step 3006. More particularly, if a therapy was effective, the patient's risk of infarction should decrease over time on a voxel-by- voxel basis.
- step 3008 it is determined whether there is a statistically significant result. If so, in step 3010 it is determined whether patient outcome improved to make a determination that the novel treatment is effective in step 3012 or a determination that the novel treatment is not effective in step 3014.
- risk maps can be assessed to determine the efficacy of one treatment and still allow the clinician the option to switch to an alternate treatment.
- the efficacy assessment can be done either by volume reduction of tissue at risk greater than a certain threshold or in quantitative terms as a red ⁇ ction of the risk values themselves as a measurable value.
- patient DWI and PWI data is acquired to generate a risk map in step 4002.
- FIG. 10 shows another embodiment utilizing a risk map as a guide for treatment planning.
- acutely acquired MRI data will be analyzed using models trained with data from N different treatments. That is, in step 5002a, the DWI/PWI data is combined using a predictive model for conventionally treated patients.
- step 5002b data is combined to generate a risk map for a first treatment option.
- step 5002c data is combined to generate a risk map for treatment option N.
- the treatment option having a risk map with the smallest volume of tissue at risk of infarction is selected. Alternatively, the treatment option that minimizes the risk, e.g. 30% instead of 80%, can be selected.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01906939A EP1255484B1 (en) | 2000-02-02 | 2001-02-02 | Method for evaluating novel stroke treatments using a tissue risk map |
DE60139457T DE60139457D1 (en) | 2000-02-02 | 2001-02-02 | UNGEN USING A TISSUE HAZARD CARD |
US10/182,978 US7020578B2 (en) | 2000-02-02 | 2001-02-02 | Method for evaluating novel, stroke treatments using a tissue risk map |
AT01906939T ATE438337T1 (en) | 2000-02-02 | 2001-02-02 | METHOD FOR EVALUATION NEW BRAIN TREATMENTS USING A TISSUE RISK MAP |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17965400P | 2000-02-02 | 2000-02-02 | |
US60/179,654 | 2000-02-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001056466A2 WO2001056466A2 (en) | 2001-08-09 |
WO2001056466A3 WO2001056466A3 (en) | 2002-05-10 |
WO2001056466A9 true WO2001056466A9 (en) | 2002-11-07 |
Family
ID=22657437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/003502 WO2001056466A2 (en) | 2000-02-02 | 2001-02-02 | Method for evaluating novel stroke treatments using a tissue risk map |
Country Status (5)
Country | Link |
---|---|
US (1) | US7020578B2 (en) |
EP (1) | EP1255484B1 (en) |
AT (1) | ATE438337T1 (en) |
DE (1) | DE60139457D1 (en) |
WO (1) | WO2001056466A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR358701A0 (en) * | 2001-03-07 | 2001-04-05 | University Of Queensland, The | Method of predicting stroke evolution |
US6904306B1 (en) * | 2002-01-23 | 2005-06-07 | Koninklijke Philips Electronics N.V. | Method and apparatus for evaluation of contrast agent uptake based on derived parametric images |
US8036730B1 (en) * | 2002-04-19 | 2011-10-11 | Fonar Corporation | Temporal magnetic resonance imaging |
US7123008B1 (en) | 2002-04-19 | 2006-10-17 | Fonar Corporation | Positional magnetic resonance imaging |
US7693727B2 (en) * | 2002-05-16 | 2010-04-06 | Cerylion, Inc. | Evidence-based checklist flow and tracking system for patient care by medical providers |
WO2004040437A1 (en) * | 2002-10-28 | 2004-05-13 | The General Hospital Corporation | Tissue disorder imaging analysis |
WO2004088345A1 (en) * | 2003-03-31 | 2004-10-14 | Koninklijke Philips Electronics N.V. | A method of magnetic resonance perfusion imaging |
US7396333B2 (en) * | 2003-08-18 | 2008-07-08 | Cardiac Pacemakers, Inc. | Prediction of disordered breathing |
US7634133B2 (en) * | 2004-03-04 | 2009-12-15 | Siemens Medical Solutions Usa, Inc. | Segmentation of structures based on curvature slope |
US7634302B2 (en) * | 2004-07-09 | 2009-12-15 | General Electric Company | Method for differentiating tissues in magnetic resonance imaging |
US7904135B2 (en) * | 2005-05-06 | 2011-03-08 | General Hospital Corporation | Magnetic resonance spatial risk map for tissue outcome prediction |
DE102005058095A1 (en) | 2005-12-05 | 2007-06-06 | Forschungszentrum Jülich GmbH | Method for the topographic representation of changes in a studied brain |
JP5105786B2 (en) * | 2006-07-07 | 2012-12-26 | 株式会社東芝 | Magnetic resonance imaging apparatus and image processing apparatus |
WO2008030192A1 (en) * | 2006-09-06 | 2008-03-13 | Agency For Science, Technology And Research | Detection and localization of vascular occlusion from angiography data |
EP2146631A4 (en) | 2007-04-13 | 2013-03-27 | Univ Michigan | Systems and methods for tissue imaging |
US20080262344A1 (en) * | 2007-04-23 | 2008-10-23 | Brummett David P | Relative value summary perfusion map |
US8602997B2 (en) | 2007-06-12 | 2013-12-10 | Sotera Wireless, Inc. | Body-worn system for measuring continuous non-invasive blood pressure (cNIBP) |
US11330988B2 (en) | 2007-06-12 | 2022-05-17 | Sotera Wireless, Inc. | Body-worn system for measuring continuous non-invasive blood pressure (cNIBP) |
WO2008154643A1 (en) | 2007-06-12 | 2008-12-18 | Triage Wireless, Inc. | Vital sign monitor for measuring blood pressure using optical, electrical, and pressure waveforms |
US11607152B2 (en) | 2007-06-12 | 2023-03-21 | Sotera Wireless, Inc. | Optical sensors for use in vital sign monitoring |
EP2282672A4 (en) * | 2008-02-29 | 2013-03-20 | Univ Michigan | Systems and methods for imaging changes in tissue |
CN102177519A (en) * | 2008-10-10 | 2011-09-07 | 皇家飞利浦电子股份有限公司 | Health-risk metric determination and/or presentation |
WO2010055405A2 (en) * | 2008-11-14 | 2010-05-20 | Apollo Medical Imaging Technology Pty Ltd | Method and system for mapping tissue status of acute stroke |
US8475370B2 (en) | 2009-05-20 | 2013-07-02 | Sotera Wireless, Inc. | Method for measuring patient motion, activity level, and posture along with PTT-based blood pressure |
US11896350B2 (en) | 2009-05-20 | 2024-02-13 | Sotera Wireless, Inc. | Cable system for generating signals for detecting motion and measuring vital signs |
US8180440B2 (en) | 2009-05-20 | 2012-05-15 | Sotera Wireless, Inc. | Alarm system that processes both motion and vital signs using specific heuristic rules and thresholds |
US10085657B2 (en) | 2009-06-17 | 2018-10-02 | Sotera Wireless, Inc. | Body-worn pulse oximeter |
US10123722B2 (en) | 2009-09-14 | 2018-11-13 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiration rate |
US11253169B2 (en) | 2009-09-14 | 2022-02-22 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiration rate |
US8527038B2 (en) | 2009-09-15 | 2013-09-03 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US10420476B2 (en) * | 2009-09-15 | 2019-09-24 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US8364250B2 (en) | 2009-09-15 | 2013-01-29 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US10213159B2 (en) | 2010-03-10 | 2019-02-26 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US10806351B2 (en) | 2009-09-15 | 2020-10-20 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US8321004B2 (en) | 2009-09-15 | 2012-11-27 | Sotera Wireless, Inc. | Body-worn vital sign monitor |
US9339209B2 (en) | 2010-04-19 | 2016-05-17 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US9173593B2 (en) | 2010-04-19 | 2015-11-03 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8979765B2 (en) | 2010-04-19 | 2015-03-17 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US9173594B2 (en) | 2010-04-19 | 2015-11-03 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8888700B2 (en) | 2010-04-19 | 2014-11-18 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
US8747330B2 (en) | 2010-04-19 | 2014-06-10 | Sotera Wireless, Inc. | Body-worn monitor for measuring respiratory rate |
SG10201510693UA (en) | 2010-12-28 | 2016-01-28 | Sotera Wireless Inc | Body-worn system for continous, noninvasive measurement of cardiac output, stroke volume, cardiac power, and blood pressure |
US8427151B2 (en) | 2011-01-14 | 2013-04-23 | National Yang-Ming University | Method and apparatus for brain perfusion magnetic resonance images |
SG192836A1 (en) | 2011-02-18 | 2013-09-30 | Sotera Wireless Inc | Modular wrist-worn processor for patient monitoring |
CN103491860B (en) | 2011-02-18 | 2016-10-19 | 索泰拉无线公司 | For measuring the optical pickocff of physiological property |
CA2840613C (en) | 2011-06-29 | 2019-09-24 | The Regents Of The University Of Michigan | Analysis of temporal changes in registered tomographic images |
US8532353B2 (en) * | 2011-11-23 | 2013-09-10 | Vital Images, Inc. | Synthetic visualization and quantification of perfusion-related tissue viability |
US9053534B2 (en) | 2011-11-23 | 2015-06-09 | The Regents Of The University Of Michigan | Voxel-based approach for disease detection and evolution |
WO2013166416A1 (en) | 2012-05-04 | 2013-11-07 | The Regents Of The University Of Michigan | Mean diffusivity measurement corrections for gradient non-linearity |
JP2015535699A (en) * | 2012-09-19 | 2015-12-17 | オーフス ウニヴァースィテット | Risk prediction of tissue infarction |
JP6017281B2 (en) * | 2012-11-27 | 2016-10-26 | 東芝メディカルシステムズ株式会社 | Stage judgment support system |
US9521291B2 (en) * | 2013-07-19 | 2016-12-13 | Digimarc Corporation | Feature-based watermark localization in digital capture systems |
CN104510470B (en) | 2013-09-29 | 2017-10-31 | 深圳先进技术研究院 | The method and apparatus that cerebral ischemia feature is determined based on Diffusion-weighted imaging |
KR101611367B1 (en) | 2013-11-18 | 2016-04-12 | 재단법인 아산사회복지재단 | Apparatus and method for servicing diagnosis of brain disease |
US20170140551A1 (en) * | 2014-06-30 | 2017-05-18 | Universität Bern | Method for segmenting and predicting tissue regions in patients with acute cerebral ischemia |
US20160188834A1 (en) * | 2014-12-31 | 2016-06-30 | Cerner Innovation, Inc. | Determination of patient-appropriate post-acute care settings |
WO2016161195A1 (en) * | 2015-03-31 | 2016-10-06 | Cortechs Labs, Inc. | Covariate modulate atlas |
US11024024B2 (en) | 2015-12-15 | 2021-06-01 | The Regents Of The University Of California | Systems and methods for analyzing perfusion-weighted medical imaging using deep neural networks |
CA3014288A1 (en) * | 2016-01-21 | 2017-07-27 | Indiana University Research And Technology Corporation | Treatment and prevention of retinal vascular disease by photocoagulation |
US10650512B2 (en) | 2016-06-14 | 2020-05-12 | The Regents Of The University Of Michigan | Systems and methods for topographical characterization of medical image data |
KR101865110B1 (en) * | 2016-11-21 | 2018-06-07 | 재단법인 아산사회복지재단 | System, method and program for estimating onset time of acute ischemic stroke |
WO2020180424A1 (en) | 2019-03-04 | 2020-09-10 | Iocurrents, Inc. | Data compression and communication using machine learning |
US11210790B1 (en) * | 2019-03-05 | 2021-12-28 | 4Qimaging, Llc | System and method for outcome-specific image enhancement |
KR102204371B1 (en) * | 2019-03-25 | 2021-01-19 | 세종대학교산학협력단 | Learning method for generating multiphase collateral image and multiphase collateral imaging method using machine learning |
GB2586119B (en) * | 2019-06-26 | 2022-04-06 | Cerebriu As | An improved medical scan protocol for in-scanner patient data acquisition analysis |
TWI767188B (en) * | 2020-02-13 | 2022-06-11 | 國立中央大學 | System for analyzing brain tissue components based on computed tomography image and operation method thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5494655A (en) * | 1990-03-09 | 1996-02-27 | The Regents Of The University Of California | Methods for detecting blood perfusion variations by magnetic resonance imaging |
US5230346A (en) * | 1992-02-04 | 1993-07-27 | The Regents Of The University Of California | Diagnosing brain conditions by quantitative electroencephalography |
US5594637A (en) * | 1993-05-26 | 1997-01-14 | Base Ten Systems, Inc. | System and method for assessing medical risk |
US20020001574A1 (en) * | 1995-12-13 | 2002-01-03 | Jon A. Woiff | Process of delivering a polynucleotide to a muscle cell via the vascular system |
US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
US5993388A (en) * | 1997-07-01 | 1999-11-30 | Kattan; Michael W. | Nomograms to aid in the treatment of prostatic cancer |
JP2002507438A (en) * | 1998-03-18 | 2002-03-12 | メディ−フィジックス・インコーポレイテッド | MR method for imaging lung and cardiac vasculature and increasing blood flow using dissolved polarized 129Xe |
US6463315B1 (en) * | 2000-01-26 | 2002-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of cerebral white matter for prognosis and diagnosis of neurological disorders |
US6700374B1 (en) * | 2000-03-29 | 2004-03-02 | Koninklijke Philips Electronics, N.V. | EPI calibration method to minimize ghosting in reconstructed images |
US6845262B2 (en) * | 2000-03-29 | 2005-01-18 | The Brigham And Women's Hospital, Inc. | Low-field MRI |
AU2002213266A1 (en) * | 2000-10-20 | 2002-05-06 | Duke University | Single-shot epi with signal recovery from susceptibility-induced losses |
US6567684B1 (en) * | 2000-11-08 | 2003-05-20 | Regents Of The University Of Michigan | Imaging system, computer, program product and method for detecting changes in rates of water diffusion in a tissue using magnetic resonance imaging (MRI) |
US20020103429A1 (en) * | 2001-01-30 | 2002-08-01 | Decharms R. Christopher | Methods for physiological monitoring, training, exercise and regulation |
US6546275B2 (en) * | 2001-06-25 | 2003-04-08 | Wisconsin Alumni Research Foundation | Determination of the arterial input function in dynamic contrast-enhanced MRI |
JP4283675B2 (en) * | 2001-09-20 | 2009-06-24 | メディ−フィジックス・インコーポレイテッド | Method for in vivo assessment of physiological status and / or organ or system function, including methods for assessing cardiopulmonary disorders such as chronic heart failure using polarized 129XE |
-
2001
- 2001-02-02 EP EP01906939A patent/EP1255484B1/en not_active Expired - Lifetime
- 2001-02-02 US US10/182,978 patent/US7020578B2/en not_active Expired - Lifetime
- 2001-02-02 AT AT01906939T patent/ATE438337T1/en not_active IP Right Cessation
- 2001-02-02 WO PCT/US2001/003502 patent/WO2001056466A2/en active Application Filing
- 2001-02-02 DE DE60139457T patent/DE60139457D1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60139457D1 (en) | 2009-09-17 |
ATE438337T1 (en) | 2009-08-15 |
EP1255484B1 (en) | 2009-08-05 |
US7020578B2 (en) | 2006-03-28 |
WO2001056466A3 (en) | 2002-05-10 |
US20040127799A1 (en) | 2004-07-01 |
EP1255484A2 (en) | 2002-11-13 |
WO2001056466A2 (en) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7020578B2 (en) | Method for evaluating novel, stroke treatments using a tissue risk map | |
Keller et al. | Preoperative automated fibre quantification predicts postoperative seizure outcome in temporal lobe epilepsy | |
Hsieh et al. | Computer-aided grading of gliomas based on local and global MRI features | |
Lin et al. | Perfusion patterns of ischemic stroke on computed tomography perfusion | |
JP7247159B2 (en) | Brain activity classifier harmonization system and brain activity classifier program | |
De Sitter et al. | Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study | |
US20240005506A1 (en) | Methods and systems for analyzing brain lesions with longitudinal 3d mri data | |
US11412977B2 (en) | Systems and methods for quantitatively characterizing Alzheimer's disease risk events based on multimodal biomarker data | |
US20210077009A1 (en) | Predicting response to therapy for adult and pediatric crohn's disease using radiomic features of mesenteric fat regions on baseline magnetic resonance enterography | |
Tran et al. | Automatic segmentation of white matter hyperintensities: validation and comparison with state-of-the-art methods on both Multiple Sclerosis and elderly subjects | |
Yazdan-Panah et al. | Automatic segmentation of the choroid plexuses: Method and validation in controls and patients with multiple sclerosis | |
Chung et al. | Stenosis detection from time-of-flight magnetic resonance angiography via deep learning 3d squeeze and excitation residual networks | |
Dong et al. | DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease | |
Yang et al. | Functional linear regression model with randomly censored data: Predicting conversion time to Alzheimer’s disease | |
Joo et al. | Fully automated radiomics-based machine learning models for multiclass classification of single brain tumors: Glioblastoma, lymphoma, and metastasis | |
Yigin et al. | Comparison of morphometric parameters in prediction of hydrocephalus using random forests | |
Sotoudeh et al. | The role of machine learning and radiomics for treatment response prediction in idiopathic normal pressure hydrocephalus | |
Vural et al. | Bright and dark vessels on stroke imaging: different sides of the same coin? | |
KR20220133151A (en) | Method, Device and Computer Program for Determining Whether to Treat Cerebral Infarction | |
Sudarshan et al. | Assessment of CT for the categorization of hemorrhagic stroke (HS) and cerebral amyloid angiopathy hemorrhage (CAAH): A review | |
Lin et al. | Diagnostic performance evaluation of adult Chiari malformation type I based on convolutional neural networks | |
Kellogg et al. | Establishment of age-and sex-specific reference cerebral ventricle volumes | |
Turk et al. | Comparative study of radiologists vs machine learning in differentiating biopsy-proven pseudoprogression and true progression in diffuse gliomas | |
KR102358865B1 (en) | Apparatus and method for diagnosing bipolar disorder using thickness of cerebellum cortex | |
Adegbite et al. | NIMG-22. COMPARISON OF NON-INVASIVE, ML-GENERATED WHOLE-BRAIN SPATIAL RADIOPATHOMIC MAPS DERIVED FROM ANATOMICAL AND DIFFUSION-WEIGHTED MRI ON PATIENTS WITH NEWLY DIAGNOSED-GLIOMA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001906939 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001906939 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10182978 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |